Research Analysts Issue Forecasts for PolyPid Q3 Earnings

Key Points

• HC Wainwright has revised down PolyPid's Q3 2025 EPS estimate to ($0.39), reflecting a shift from their previous estimate of ($0.36), while maintaining a "Buy" rating with a $13.00 price target.
• PolyPid reported a Q2 earnings miss with an EPS of ($0.78), falling short of analyst expectations which were set at ($0.53).
• The company's current market cap stands at $54.54 million, with a 52-week price range between $2.30 and $3.93.

PolyPid Ltd. (NASDAQ:PYPD - Free Report) - HC Wainwright decreased their Q3 2025 EPS estimates for PolyPid in a report issued on Wednesday, August 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.39) for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid's current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid's FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $1.46 EPS.

PYPD has been the topic of several other research reports. Roth Capital restated a "buy" rating on shares of PolyPid in a report on Thursday. Craig Hallum reissued a "buy" rating and issued a $13.00 price objective (down from $15.00) on shares of PolyPid in a research report on Thursday. Wall Street Zen raised PolyPid to a "hold" rating in a research report on Saturday, July 12th. Finally, JMP Securities lowered their target price on PolyPid from $16.00 to $14.00 and set a "market outperform" rating for the company in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $12.40.

PolyPid Price Performance

PYPD opened at $3.43 on Friday. PolyPid has a 52-week low of $2.30 and a 52-week high of $3.93. The company has a 50 day moving average of $3.49 and a two-hundred day moving average of $3.05. The company has a market cap of $54.54 million, a P/E ratio of -0.90 and a beta of 1.40. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 4.43.

PolyPid (NASDAQ:PYPD - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.25).

Institutional Trading of PolyPid

A number of hedge funds have recently made changes to their positions in the stock. Lumbard & Kellner LLC acquired a new stake in PolyPid in the second quarter valued at $135,000. J. Goldman & Co LP bought a new stake in shares of PolyPid in the 4th quarter worth about $391,000. Finally, AIGH Capital Management LLC lifted its position in shares of PolyPid by 13.6% during the first quarter. AIGH Capital Management LLC now owns 940,381 shares of the company's stock worth $2,548,000 after purchasing an additional 112,514 shares during the last quarter. Institutional investors and hedge funds own 26.47% of the company's stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.